reports
Hybridan Small Cap Feast - 21 November 2024
* A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: None Delistings: None What’s baking in the oven? Reverse Takeover: 18 November 2024: Greatland Gold (GGP.L) has entered into an agreement with certain subsidiaries of Newmont...
- Martin Hall
Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Pro...
Shield is a commercial-stage pharma company delivering specialty products that address the needs of patients with iron deficiency (ID). Since its July 2021 US launch, Shield and Viatris have increased physician awareness of the differentiating characteristics of ACCRUFeR® as an oral ID drug, in order to generate sales traction. The 3Q’24 trading update reiterated the interim statement dialog: sales continue to progress, while costs are being actively managed. Shield is being proactive, extending...
Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Pro...
Hardman & Co Research Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven 21-Nov-2024 / 11:15 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven Shield is a commercial-stage pharma company delivering specialty products that address the needs of patients with iron deficiency (ID). Since its July 2021 US launch, Shield and Viatris have increased physician awareness of the diffe...
Hardman & Co Video Event: Shield Therapeutics (STX) Investor Forum
Hardman & Co Research Hardman & Co Video Event: Shield Therapeutics (STX) Investor Forum 11-Nov-2024 / 14:00 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Video Event | Shield Therapeutics (STX) Investor Forum We are delighted to announce that Shield Therapeutics (STX) will be presenting at Hardman & Co's upcoming Investor Forum at 3:00pm this Thursday 14 November 2024. to secure your place and submit questions. A commercial-stage pharmaceutical company, Shield Therapeutics is strategically positioned to address the significant u...
- Mark Thomas
- Martin Hall
The Hardman & Co Monthly: November 2024
Feature article: “ROOM” (Running Out of Money) risk, How managing liquidity risk can sustain corporate value and maintain shareholder confidence As we come close to the end of a very challenging year for many UK entrepreneurs, as well as a frustrating period for shareholders, it is time to address one elephant in the ROOM! ROOM stands for “Running Out of Money”. The risk of doing so, or the perception that it could occur, can destroy corporate values and prematurely paralyse a business. While ...
Hybridan Small Cap Feast - 29 October 2024
* A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: None Delistings: None What’s baking in the oven? ITF announced:*** Potential** Initial Public Offerings: 17th October 2024: Selkirk Group, a newly incorporated company establ...
- Brian Moretta
- Keith Hiscock
- Mark Thomas
- Martin Hall
Hardman & Co Monthly: October 2024
Feature article: Labour’s first Budget - Investors in their sights? Summary ► Budgets are always important for investors. ► The imminent Budget, at the end of October, will be doubly so, because it is the first from the new Labour government, and it has already signalled the need to fill an alleged £22bn black hole, while ruling out changes to more than half the tax base. That implies a lot of the pain will be felt by investors. ► This paper considers the impact of increases in rates for th...
Hybridan Friday Takeaway - 27 September 2024
27th September 2024 GENinCode 5.4p £9.5m (GENI.L) A specialist in predictive genetics used in patient risk assessment focusing on cardiovascular disease, (CVD), and Ovarian Cancer. CVD includes stroke, heart failure, hypertension and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the US. Its Interim to June 2024 reported revenue increasing 46% to £1.39m, helped by the first US commercial sales for its LIPID inCode test for the diagnosis of familial h...
Hybridan Small Cap Feast - 25 September 2024
25th September 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: None Whats baking in the oven? Potential**** Initial Public Offerings: ITF announced: GenIP aims to list on the AIM market on 2 October 2024. It is targeting to raise £1.5m and anticipating a £6.5m market cap. GenIP is a portfolio...
- Martin Hall
Tissue Regenix (TRX): Maiden pre-tax profit
TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated seven consecutive reporting periods of strong growth, with TRX becoming profitable in 1H’24. TRX is about to invest...
Hardman & Co Research on Tissue Regenix (TRX): Maiden pre-tax profit
Hardman & Co Research Hardman & Co Research on Tissue Regenix (TRX): Maiden pre-tax profit 23-Sep-2024 / 07:15 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Tissue Regenix (TRX): Maiden pre-tax profit TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue processing, manufacturing capacity and strong comm...
- Martin Hall
Shield Therapeutics (STX): Focusing on successful execution
Shield is a commercial-stage pharma company delivering specialty products that address the unmet medical need of patients with iron deficiency (ID). Since its July 2021 US launch, Shield and Viatris have increased physician awareness of the differentiating characteristics of ACCRUFeR® as an oral ID drug, in order to generate sales traction. 1H’24 results have confirmed that sales continue to progress well, while costs have been closely controlled. Management is focused on successful execution an...
Hardman & Co Research on Shield Therapeutics (STX): Focusing on succes...
Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Focusing on successful execution 11-Sep-2024 / 12:25 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Shield Therapeutics (STX): Focusing on successful execution Shield is a commercial-stage pharma company delivering specialty products that address the unmet medical need of patients with iron deficiency (ID). Since its July 2021 US launch, Shield and Viatris have increased physician awareness of the differentiating characteristics of ACCRUFeR® as a...
Hybridan Small Cap Feast - 4 September 2024
4th September 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: Mattioli Woods (MTW.L) has delisted from AIM What’s baking in the oven ? Our daily digest of news from UK Small Caps If you would like to unsubscribe, please email with “unsubscribe me”. Hybridan Chefs Banquet Buffet*** Accsys ...
- Brian Moretta
- Mark Thomas
- Martin Hall
Hardman & Co Monthly: September 2024
Feature article: The Tiktok generation are becoming “renegade” investors - How Gen Z’s investing habits differ from past generations As the landscape of investing evolves, a new generation is stepping onto the stage with fresh perspectives and unique approaches that are reshaping financial markets. At Hardman & Co, we’ve always been committed to understanding these shifts, and this month’s article delves into the rapidly changing ways in which Gen Z interacts with investment information and ma...
- Mark Thomas
- Martin Hall
- Nigel Hawkins
Hardman & Co Monthly: August 2024
Feature article: Solid IICs, cash-consolidating REIFs Since the beginning of 2024, the share prices of Infrastructure Investment Companies (IICs) and Renewable Energy Infrastructure Funds (REIFs) have generally remained lacklustre, failing to recover from the losses experienced in 2023. A significant factor contributing to this trend has been the sharp rise in interest rates since 2021, which has negatively impacted the sector due to the increased yields on “risk-free” 10-year gilts. The recent...
Hybridan Small Cap Feast - 24 July 2024
24th July 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: None What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 8th July 2024: Rome Resources: The Canada-based early-stage resource exploration Company has announced its intention to IPO on AIM in order to co...
Hybridan Small Cap Feast - 16 July 2024
16th July 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: None What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 8th July 2024: Rome Resources: The Canada-based early-stage resource exploration Company has announced its intention to IPO on AIM in order to co...
- Mark Thomas
- Martin Hall
- Mike Foster
Hardman & Co Monthly: July 2024
Feature article: UK life sciences needs more local institutional support to survive. For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices. This is quite unusual for healthcare stocks. Apart from the general economic influences, which have made institutions more risk-averse, there was a common knowledge that several companies were in need of additional working capital; so, share prices were marked down in anticipa...
Hybridan Small Cap Feast - 3 July 2024
3rd July 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: IntelliAM AI plc (AQSE: INT) has joined the Aquis Stock Exchange Growth Market. IntelliAM, an artificial intelligence company focused on the consumer goods industry, acquired 53 Degrees North Engineering Limited, to become the Company’s Consultancy divi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.